Iterum Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary

Iterum Therapeutics

05/08/2025 14:32

Iterum Therapeutics PLC ITRM.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -30 cents.  The mean expectation of two analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -13 cents to -9 cents per share.

Reported revenue was zero​; analysts expected zero.

Iterum Therapeutics PLC's reported EPS for the quarter was a loss of 16 cents​.

The company reported a quarterly loss of $6.51 million.

Iterum Therapeutics PLC shares had fallen by 28.3% this quarter and lost 59.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 26.7% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Iterum Therapeutics PLC is $7.00, about 89.8% above its last closing price of $0.71

This summary was machine generated from LSEG data August 5 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.11
-0.16
Missed
Mar. 31 2025
-0.14
-0.14
Met
Dec. 31 2024
-0.21
-0.23
Missed
Sep. 30 2024
-0.20
-0.30
Missed